{"id":187062,"date":"2024-04-09T16:25:46","date_gmt":"2024-04-09T21:25:46","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/04\/repotrectinib-shrinks-ros1-positive-nsclc-tumors"},"modified":"2024-04-09T16:25:46","modified_gmt":"2024-04-09T21:25:46","slug":"repotrectinib-shrinks-ros1-positive-nsclc-tumors","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/04\/repotrectinib-shrinks-ros1-positive-nsclc-tumors","title":{"rendered":"Repotrectinib Shrinks ROS1-Positive NSCLC Tumors"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/repotrectinib-shrinks-ros1-positive-nsclc-tumors2.jpg\"><\/a><\/p>\n<p>For many of these individuals, the response to repotrectinib lasted for several years.<\/p>\n<p>\u201cRepotrectinib can lead to long-term responses for patients with ROS1 fusion\u2013positive lung cancers, including those who have and have not received prior targeted therapy,\u201d said Alexander Drilon, M.D., of Memorial Sloan Kettering Cancer Center, who led the TRIDENT-1 study.<\/p>\n<p>Treatment with repotrectinib also shrank tumors that had spread to the brain, a common location for lung metastases, the researchers reported.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>For many of these individuals, the response to repotrectinib lasted for several years. \u201cRepotrectinib can lead to long-term responses for patients with ROS1 fusion\u2013positive lung cancers, including those who have and have not received prior targeted therapy,\u201d said Alexander Drilon, M.D., of Memorial Sloan Kettering Cancer Center, who led the TRIDENT-1 study. Treatment with repotrectinib [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-187062","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/187062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=187062"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/187062\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=187062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=187062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=187062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}